E. Kevin Hrusovsky Net Worth

The estimated Net Worth of E Kevin Hrusovsky is at least $20.9 Million dollars as of 12 June 2024. Mr. Hrusovsky owns over 7,777 units of Quanterix Corp stock worth over $1,689,112 and over the last 13 years he sold QTRX stock worth over $15,574,314. In addition, he makes $3,631,000 as Chairman of the Board, President und Chief Executive Officer at Quanterix Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Hrusovsky QTRX stock SEC Form 4 insiders trading

E has made over 96 trades of the Quanterix Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 7,777 units of QTRX stock worth $93,868 on 12 June 2024.

The largest trade he's ever made was exercising 76,016 units of Quanterix Corp stock on 21 November 2022 worth over $26,606. On average, E trades about 5,548 units every 23 days since 2012. As of 12 June 2024 he still owns at least 139,943 units of Quanterix Corp stock.

You can see the complete history of Mr. Hrusovsky stock trades at the bottom of the page.

E. Kevin Hrusovsky biography

E. Kevin Hrusovsky serves as Chairman of the Board, President, Chief Executive Officer of the Company. Prior to joining us, Mr. Hrusovsky served as Senior Vice President of PerkinElmer, Inc., a publicly traded company that produces analytical instruments, genetic testing and diagnostic tools, medical imaging components, software, instruments and consumables for multiple end markets, from February 2012 to May 2013 and served as President of the Life Sciences and Technology business unit of PerkinElmer, Inc. from November 2011 to May 2013. From May 2013 through September 2013, he served as a consultant to PerkinElmer. Previously, Mr. Hrusovsky served as Chief Executive Officer and President of Caliper Life Sciences, Inc., a life sciences company that developed and sold lab automation equipment, from July 2003 to November 2011 when it was acquired by PerkinElmer, Inc. Prior to that, he served as Chief Executive Officer and President of Zymark, a company that provided laboratory automation, robotics, and liquid handling solutions, and Director of International Business, Agricultural Chemical Division, and President of the Pharmaceutical Division for FMC Corporation, a publicly traded chemical manufacturing company. He also held several management positions at E.I. DuPont de Nemours, a publicly traded chemical manufacturing company. Mr. Hrusovsky serves on the boards of directors of several private companies, including BioreclamationIVT, LLC, Cellaria, Cell Signaling Technology, Inc., 908 Devices Inc., and Solect Energy Development, LLC, and is the founder of the Powering Precision Health Summit, an executive think tank of researchers, scientists, physicians and innovators focused on the latest research on new biomarkers that have the potential to advance personalized medicine.

What is the salary of E Hrusovsky?

As the Chairman of the Board, President und Chief Executive Officer of Quanterix Corp, the total compensation of E Hrusovsky at Quanterix Corp is $3,631,000. There are no executives at Quanterix Corp getting paid more.

How old is E Hrusovsky?

E Hrusovsky is 58, he's been the Chairman of the Board, President und Chief Executive Officer of Quanterix Corp since 2015. There are 11 older and 9 younger executives at Quanterix Corp. The oldest executive at Quanterix Corp is Dr. David R. Walt Ph.D., 68, who is the Co-Founder, Chairman of Scientific Advisory Board & Independent Director.

What's E Hrusovsky's mailing address?

E's mailing address filed with the SEC is C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON, MA, 02210.

Insiders trading at Quanterix Corp

Over the last 7 years, insiders at Quanterix Corp have traded over $25,118,881 worth of Quanterix Corp stock and bought 1,481,095 units worth $18,701,541 . The most active insiders traders include David R Walt, Paul M Meister und Keith Crandell. On average, Quanterix Corp executives and independent directors trade stock every 7 days with the average trade being worth of $100,483. The most recent stock trade was executed by Masoud Toloue on 13 August 2024, trading 19,000 units of QTRX stock currently worth $207,100.

What does Quanterix Corp do?

quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).

Complete history of Mr. Hrusovsky stock trades at Revvity, Quanterix Corp und 908 Devices

Quanterix Corp executives and stock owners

Quanterix Corp executives and other stock owners filed with the SEC include:

• E. Kevin Hrusovsky,
  Chairman of the Board, President, Chief Executive Officer
• John Fry,
  General Counsel, Secretary
• Amol Chaubal,
  Chief Financial Officer
• E. Kevin Hrusovsky,
  Chairman & CEO
• Dawn Mattoon,
  Senior Vice President - Research Products
• David Duffy,
  Senior Vice President, Research & Development and Chief Technology Officer
• Sarah Hlavinka,
  Independent Director
• Mark Roskey,
  Senior Vice President - Commercial and Accelerator
• Martin Madaus,
  Lead Independent Director
• Paul Meister,
  Independent Director
• Keith Crandell,
  Independent Director
• Marijn Dekkers,
  Independent Director
• David Walt,
  Independent Director
• Dr. David R. Walt Ph.D.,
  Co-Founder, Chairman of Scientific Advisory Board & Independent Director
• William Geist,
  Chief Operating Officer
• Dr. Masoud Toloue Ph.D.,
  Pres, CEO & Director
• Dr. Dawn R. Mattoon Ph.D.,
  Sr. VP of Diagnostics
• Dr. Mark T. Roskey Ph.D.,
  Sr. VP of Strategic Partnerships
• Dr. David C. Duffy Ph.D.,
  Sr. VP of R&D and CTO
• Michael A. Doyle,
  CFO & Treasurer
• Masoud Toloue,
  Pres & Head of Diagnostics Bus.
• David Panzerella,
  VP of Sales
• William Geist,
  Chief Operating Officer
• Bruce J. Bal,
  VP of Operations, Service & Quality
• John J. Fry,
  Gen. Counsel & Corp. Sec.
• Brian J Blaser,
  
• Shawn Stetson,
  Interim CFO and Treasurer
• Venture Fund Vi Lparch Vent...,
  
• Ventures Fund 2004 L P Flag...,
  
• Capital Venture Investors, ...,
  
• Ernest Orticerio,
  SVP Finance and Corporate Dev
• Douglas G. Cole,
  
• John M Connolly,
  
• Jackson Streeter,
  SVP, Corp Dev & Strategy
• Bruce J Bal,
  VP of Ops, Service and Quality
• Joseph Driscoll,
  Chief Financial Officer
• Amee Desjourdy,
  Chief Human Resource Officer
• Laurie J Olson,
  
• Michael A Doyle,
  CFO and Treasurer
• Masoud Toloue,
  President & CEO
• Karen Flynn,
  
• William P Donnelly,
  
• Vandana Sriram,
  Chief Financial Officer
• Jeffrey Thomas Elliott,